FAQs about Stalevo

Category: Stalevo

The U.S. Food and Drug Administration approved Stalevo in June 2003 to treat people with Parkinson’s disease. Indications include the use of Stalevo for patients already on levodopa/carbidopa plus entacapone as separate medications, as well as its administration as a replacement treatment for people experiencing motor fluctuations despite being on optimal carbidopa/levodopa therapy.

Category: Stalevo

Although animal studies have shown that Stalevo could potentially harm a developing fetus, it is unclear how it affects pregnant patients and babies due to the lack of clinical data. Therefore, it is uncertain whether Stalevo is safe to use during pregnancy. Patients who plan to become pregnant while on the medication are advised to consult with their healthcare provider.

Category: Stalevo

Individuals who are taking Stalevo may experience severe drowsiness or sudden episodes of falling asleep while performing daily activities. To avoid any potential risks, it is important that patients starting this treatment refrain from driving or engaging in any potentially hazardous activities until they understand how the medication affects them. If these adverse events occur, it is recommended patients consult with their doctor about potentially discontinuing treatment.

Category: Stalevo

Based on clinical trial data, Stalevo can result in significant benefits for patients as early as after eight weeks following the start of treatment. However, because the treatment may require initial dose adjustments, the timeframe for seeing the full benefits from Stalevo can vary depending on the person and the stage of the individual’s Parkinson’s disease.

Category: Stalevo

While clinical trials have not reported hair loss or weight gain as side effects of Stalevo, some individuals taking levodopa-based medications have reported hair loss. Additionally, weight gain can occur due to compulsive eating, which is a potential side effect of the medication. Patients who experience hair loss or weight gain after starting Stalevo should discuss these issues with their healthcare providers.